The overexpression of salivary cytokeratins as potential diagnostic biomarkers in head and neck squamous cell carcinomas by Tang, Kai Dun et al.
Oncotarget72272www.impactjournals.com/oncotarget
The overexpression of salivary cytokeratins as potential 
diagnostic biomarkers in head and neck squamous cell 
carcinomas
Kai Dun Tang1,2, Liz Kenny3,4, Chris Perry5, Ian Frazer6 and Chamindie Punyadeera1,2
1The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, 
Kelvin Grove, Queensland, Australia
2The Translational Research Institute, Woolloongabba, Australia 
3School of Medicine, University of Queensland, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia 
4Central Integrated Regional Cancer Service, Queensland Health, Brisbane, Queensland, Australia 
5Department of Otolaryngology, Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
6The University of Queensland Diamantina Institute, Translational Research Institute, Woolloongabba, Queensland, Australia
Correspondence to: Chamindie Punyadeera, email: chamindie.punyadeera@qut.edu.au
Keywords: saliva, cytokeratin, head and neck squamous cell carcinoma, human papillomavirus
Received: May 17, 2017    Accepted: June 28, 2017    Published: July 31, 2017
Copyright: Tang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source 
are credited.
ABSTRACT
Background: Cytokeratin (CK) intermediate filaments are demonstrated to have 
enormous potential in regulating cellular motility and cancer progression. There are 
more than 20 divergent CKs that have been identified, of which CK 8, 17, 18 and 19 are 
reported to be elevated in the tumour biopsies of head and neck cancer squamous cell 
carcinoma (HNSCC) patients. However, CK expression profiles in the saliva of HNSCC 
patients have not been investigated. We aim to investigate the mRNA expression 
profiles of CKs in saliva collected from healthy controls, HPV-negative and -positive 
HNSCC patients.
Methods: Oral rinse samples were collected from 42 cancer-free healthy controls 
(age-matched) and patients who have been diagnosed with HPV-negative (n = 20) 
and -positive (n = 48) HNSCC.
Results: Here, we report that the mRNA expression profiles of CKs differed in 
saliva collected from healthy controls and HNSCC patients. The mRNA expression 
levels of CK 8 and 18 were significantly elevated in saliva collected from HPV-negative 
HNSCC patients; whilst, CK 17 and 19 were expressed at a higher mRNA level in 
saliva collected from HPV-positive HNSCC patients compared to healthy controls. 
Importantly, receiver operating characteristic (ROC) analysis showed salivary CK 8 
and 18 to have superior sensitivity and specificity in discriminating the HPV-negative 
HNSCC patients from healthy controls (80% and 86%) as well as between HPV-
negative and -positive HNSCC patients (75% and 81%).
Conclusion: In summary, we have demonstrated that an aberrant expression of 
salivary CKs may serve as a potential non-invasive diagnostic biomarker in HNSCC.
INTRODUCTION
Head and neck cancer is a heterogeneous group 
of tumours arising from various anatomic structures 
including the nasal and oral cavity, oropharynx, larynx and 
hypopharynx [1]. More than 90% of these are head and 
neck squamous cell carcinomas (HNSCC) [2] and is the 
sixth most common cancer worldwide [3]. The incidence of 
HNSCC associated with traditional risk factors (tobacco use 
and alcohol consumption) is declining, whereas high-risk 
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human papillomavirus (HPV)-positive HNSCC incidence is 
increasing in the western world, [4–8] including Australia [9].
Although the major risk factors for HNSCC are 
identified and have been used as prognostic biomarkers in 
the recent decades, disappointingly, there is no significant 
improvement in the overall survival rates of HNSCC (<50% 
survival in five years) compared to other cancer types like 
breast, colorectal and prostate [10–12]. This may be due 
to the high frequency of locoregional recurrences, limiting 
the development of new therapeutic strategies for HNSCC 
patients. Furthermore, most of these tumours are tiny in the 
early stages of tumour progression and are located in obscure 
regions of the head and neck anatomy, leading to misdiagnosis 
[13]. Therefore, saliva has been championed as the next 
generation body fluid by virtue of convenience sampling, 
non-invasive nature and serial sampling capabilities aiming 
at broader community-based screening [14–17].
Cytokeratins (CKs) are a family of cytoskeletal 
intermediate filament proteins that are commonly found in 
epithelial tissues [18]. CKs can be classified into two main 
groups according to their molecular weight and isoelectric 
point: Type I and Type II. Type I CKs (9 to 20) are more 
acidic and have a smaller molecular weight (40 - 64 kDa); 
whereas Type II CKs (1 to 8) are considered as neutral or 
basic and have a relatively large molecular weight (52 - 
68 kDa) [19]. The expression of CKs can be sub-divided 
into categories depending on the degree of epithelial cells 
differentiation and maturation [20, 21]. For instance, 
cornified cells express CK 1, 2, 10 and 11; stratified cells 
express CK 4 and 13; basal cells express CK 5 and 14; 
hyperproliferative cells express CK 6 and 16 and simple 
cells express CK 7, 8, 18 and 19 [22–24]. As reported by 
previous studies, tissue polypeptide antigen (TPA), tissue 
polypeptide specific antigen (TPS), and CYFRA 21-1 
are the most commonly used CK biomarker in various 
epithelial cell-associated carcinomas [25–27].
The aberrant expression of CKs has been reported 
to be associated with HNSCC tumour development and 
progression [28–30]. Indeed, these studies have only 
focused on investigating the diagnostic potential of CKs 
expression in both tumour biopsies and plasma, not in 
saliva. We hypothesized that the overexpression of CKs 
in saliva can be served as a potential diagnostic biomarker 
to discriminate healthy controls from HPV-negative and 
-positive patients. The aims of this study were two-fold: 
firstly, to investigate the mRNA expression profiles of 
CKs in saliva collected from healthy controls and HNSCC 
patients. Secondly, to determine the diagnostic potential of 
salivary CK mRNA expression levels in HNSCC.
RESULTS
Population characteristics
Healthy controls (n=42) and HNSCC patients (n=20 
for HPV-negative HNSCC and n=48 for HPV-positive 
HNSCC) were recruited in this study (refer to Table 1). 
Most of the participants were male (70%) compared with 
females (30%). The mean age for healthy controls were 
54 years (SD = 10; range = 33 – 72 years); HPV-negative 
HNSCC patients were 60 years (SD = 11; range = 20 – 
92 years) and HPV-positive HNSCC patients were 63 
years (SD = 13.2; range = 32 -87 years). The majority 
ethnicity in healthy controls, HPV-negative and -postive 
HNSCC patients were Caucasian, 92.9%, 95% and 98%, 
respectively. Healthy controls were more susceptible to 
be non-smokers than HPV-negative and -positive HNSCC 
patients. Healthy controls (42.9%) were classified as non-
smokers, whilst 20% and 37.5% of HPV-negative and 
-positive HNSCC patients were non-smokers. About 80% 
of HPV-negative HNSCC patients were current and former 
smokers, whilst current and former smokers in the healthy 
controls and HPV-positive patients were 45% and 62% 
respectively.
According to the TNM classification system of 
AJCC for HPV-negative and -positive HNSCC patient 
staging was as follows: Stage I (5% and 4.2%), II (0% and 
2.1%), III (30% and 10.4%), IVa (30% and 70.8%), IVb 
(20% and 10.4%) and IVc (0% and 2.1%) respectively. 
Most cases of HPV-negative and -positive HNSCC 
patients were diagnosed at an advanced stage IV (49 of 
66; 72%). HPV-negative HNSCC cancer sites were mostly 
oropharyngeal and oral cavity (50% and 25%) whilst 
laryngeal, hypopharyngeal and nasopharyngeal were 5%, 
15% and 5% respectively. Compared to HPV-negative 
HNSCC patients, the most common anatomical site found 
in HPV-positive HNSCC patients were oropharyngeal 
and oral cavity (91.7% and 8.3%). There were few cases 
of well differentiated squamous cell carcinoma found in 
both HPV-negative and -positive HNSCC patients. Most 
of the HPV-negative (75%) and -positive (50%) HNSCC 
patients were considered as moderate and poor squamous 
cell carcinoma.
The mRNA expression levels of cytokeratin 
in saliva collected from healthy controls and 
HNSCC patients
Although CK is one of the well-known tumour 
biomarkers for a number of tumour types including 
HNSCC, its expression level in saliva still remains to be 
elucidated. To address this question, we first investigated 
whether the saliva collected from healthy controls and 
HNSCC patients express the mRNA levels of CK 8, 13, 17, 
18 and 19. As shown in Figure 1, the mRNA expression 
levels of CK 17, 18 and 19 was significantly upregulated 
in saliva collected from HNSCC patients compared to 
healthy controls, albeit CK 8 and 13. However, there was 
only a slightly upregulation of CK 8 mRNA expression 
level in the saliva collected from HNSCC patients 
compared to healthy control. Hierarchical clustering 
analysis revealed that the CKs mRNA expression patterns 
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Table 1: Participants demographic characteristics
HNSCC Patients
Controls HPV-negative HPV-positive
(n = 42) (n = 20) (n = 48)
Gender
Male 29 (69.0) 16 (80.0) 46 (95.8)
Female 13 (31.0) 4 (20.0) 2 (4.2)
Age (years)
<50 13 (30.9) 2 (10.0) 7 (14.6)
50 - 60 17 (40.5) 4 (20.0) 17 (35.4)
>60 12 (28.6) 14 (70.0) 24 (50.0)
Race and ethnicity
Caucasian 39 (92.9) 19 (95.0) 47 (98.0)
Other 3 (7.1) 1 (5.0) 1 (2.0)
Smoking status
Smokers 4 (9.5) 5 (25.0) 4 (8.3)
Ex-smoker 15 (35.7) 11 (55.0) 26 (54.2)
Non-smoker 18 (42.9) 4 (20.0) 18 (37.5)
N/A 5 (11.9) 0 (0) 0 (0)
Tumour characteristics
 AJCC TNM Stage I 1 (5.0) 2 (4.2)
 Stage II 0 (0) 1 (2.1)
 Stage III 6 (30.0) 5 (10.4)
 Stage IVa 6 (30.0) 34 (70.8)
 Stage IVb 3 (20.0) 5 (10.4)
 Stage IVc 0 (0) 1 (2.1)
 N/A 3 (15.0) 0 (0)
Tumour anatomic sites
Oral cavity 5 (25.0) 4 (8.3)
Oropharynx 10 (50.0) 44 (91.7)
Larynx 1 (5.0) 0 (0)
Hypopharynx 3 (15.0) 0 (0)
Nasopahrynx 1 (5.0) 0 (0)
Differentiation status
Well differentiated 0 (0) 0 (0)
Well to moderately differentiated 2 (10.0) 3 (6.3)
Moderately differentiated 10 (50.0) 9 (18.8)
Moderately to poorly 
differentiated
2 (10.0) 6 (12.5)
Poorly differentiated 3 (15.0) 10 (20.8)
N/A 3 (15.0) 20 (41.7)
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in saliva differed between healthy controls and HNSCC 
patients as shown in Supplementary Figure 1. These 
data strongly support the notion that tumour biopsies can 
potentially be replaced by saliva in the future.
The overexpression of cytokeratin 8 and 18 
mRNA levels in saliva collected from HPV-
negative HNSCC patients
Current literature reports that the expression of CKs 
is able to distinguish the HPV status in HNSCC patients 
[31] and hence, we hypothesized that its expression in 
saliva will potentially have similar expression trend 
as in tumor biopsies. As shown in Figure 2, the mRNA 
expression levels of CK 8 and 18 were significantly 
upregulated in saliva collected from HPV-negative 
HNSCC patients compared to healthy controls and HPV-
positive HNSCC patients. Interestingly, no significant 
increase in both CK 8 mRNA levels was detectable in 
saliva collected from HPV-positive HNSCC patients 
when compared to healthy controls. Most importantly, 
using ROC curve analysis, the mRNA expression levels 
of CK 8 and 18 in saliva was able to distinguish the 
HPV-negative HNSCC patients from the healthy controls 
(Area under the curve (AUC) = 0.85, Sensitivity 80% and 
Specificity 86%, Positive predictive values (PPV) 90.0% 
and Negative predictive values (NPV) 72.7%) as well as 
between HPV-negative and -positive HNSCC patients 
(AUC = 0.77, Sensitivity 75% and Specificity 81%, PPV 
88.7% and NPV 62.5%) as shown in Figure 3A and 3B. 
These findings further support the potential clinical utility 
of salivary CK 8 and 18 in differential diagnosis between 
HPV-negative and -positive HNSCC patients.
The overexpression of cytokeratin 17 and 19 
mRNA levels in saliva collected from HPV-
positive HNSCC
Conversely, the mRNA expression levels of CK 17 
and 19 were significantly elevated in saliva collected from 
HPV-positive patients compared to healthy controls as 
shown in Figure 2. However, the mRNA expression levels 
of CK 17 and 19 in saliva did not show any significant 
differences between healthy controls and HPV-negative 
HNSCC patients as well as HPV-negative and -positive 
HNSCC patients. Taken together, these results clearly 
highlight the potential diagnostic value of salivary CK 17 
and 19 in discriminating the HPV status in HNSCC.
Figure 1: The mRNA relative expression level of CK 8, 13, 17, 18 and 19 in saliva collected from healthy controls (n=42) 
and HNSCC patients (n=68) using RT-qPCR. Results were normalized to an internal control (beta-actin) and are presented as delta 
Ct values. Statistically significant differences (p < 0.05) were determined using Mann-Whitney U-test. (p values: ** < 0.005, *** < 0.001).
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Figure 2: The mRNA relative expression level of CK 8, 13, 17, 18 and 19 in saliva collected from healthy controls 
(n=42), HPV-negative (n=20) and -positive HNSCC patients (n=48) by RT-qPCR. Results were normalized with internal 
control and are presented as delta Ct values. Statistically significant differences (p < 0.05) among these three groups were determined using 
ordinary one way ANOVA. (p values: * < 0.05, ** < 0.005, *** < 0.001, **** < 0.0001).
Figure 3: The receiver operator characteristic (ROC) curve analysis for the mRNA expression level of salivary CK 8 
and 18 in healthy controls and HNSCC patients, indicating an area under the curve (AUC) with the diagnostic power to 
discriminate the HPV-negative HNSCC patients from healthy controls (A) as well as between HPV-negative and -positive 
HNSCC patients (B).
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DISCUSSION
The clinical diagnosis in HNSCC patients is 
challenging compared to other cancers as they are 
difficult to radiologically resolve due to the tumour size 
and anatomical region [13]. Therefore, diagnostic and 
predictive biomarkers are urgently needed to improve 
overall survival rates in HNSCC patients. Human saliva 
is a unique body fluid which has been widely used as 
non-invasive diagnostic markers for HNSCC [32–34]. 
Owing to its close proximity to the oral cavity, tumours 
may secrete and/or shed tumour-specific biomolecules 
directly into saliva. We are the first group to demonstrate 
that the expression profile of CKs in saliva collected from 
HNSCC patients is strongly correlated with blood and 
tissues expression levels from HNSCC patients. More 
importantly, the mRNA expression profile of CKs in saliva 
is able to discriminate the HPV-negative HNSCC from 
HPV-positive HNSCC.
Ample evidence has suggested that the CKs 
expression profile is associated with a range of different 
cancers including breast, colorectal, prostate and head and 
neck [30, 35–37]. Notably, CK 8, 17 and 18 were elevated 
in HNSCC tumour tissues compared to normal tissues 
[29, 38, 39]. The circulating fragments of CK 19 were 
significantly increased in the serum and saliva collected 
from HNSCC [40–42]. Similarly, in our saliva study, 
compared to healthy controls, HNSCC patients expressed 
a higher level of CK 17, 18 and 19 mRNA. Surprisingly, 
there was no significant difference between the CK 8 
and 13 mRNA expression levels in saliva from HNSCC 
patients when compared to healthy controls.
Recent studies reported that the majority of HPV-
positive HNSCC tumours have distinct phenotypes. 
This was confirmed by our immunohistochemistry 
(IHC) results that most of them have a non-keratinizing 
morphology with basal cell features [43, 44] (data not 
shown), clearly demonstrating the diagnostic potential of 
CKs to discriminate the HPV status in HNSCC. It is worth 
noting that there is an association between CKs and HPV 
infection, but also their underlying mechanism. In both in 
vitro and in vivo studies, high-risk type HPV-16 E1^E4 
was found to interfere and collapse the structure of CK 8 
and 18 networks in the cytoplasm [45]. Consistent with 
previous studies, the mRNA expression levels of CK 8 
and 18 were downregulated in saliva samples collected 
from HPV-positive HNSCC patients compared with HPV-
negative HNSCC patients.
Intriguingly, our study was in line with previous 
studies that observed the upregulation of CK 17 and 19 
mRNA expression levels in saliva collected from HPV-
positive HNSCC patients. According to Hobbs et al., CK 
17 was significantly upregulated in HPV-16 mouse models 
compared to wild type, suggesting the possible association 
between HPV-16 infection and CK 17 expression [46]. 
Meanwhile, Favia et al. demonstrated for the first time 
that CK 19 induced the protein expression of HPV E7, 
an oncogene that plays a major role in promoting the 
carcinogenesis of HNSCC via the release of viral E7 
mRNA from the translational block controlled by CK 7 
[47]. Further evidence is supported by Santoro et al. which 
CK 19 suggested as a potential differential diagnostic 
marker to discriminate the HPV status in HNSCC [20].
Aside from being employed as a diagnostic 
biomarker, CKs are also found to harbour potential 
prognostic value in various epithelial cell-associated 
carcinomas [48–50]. Importantly, numerous studies have 
shown the significant correlation between CKs (especially 
8, 18 and 19) and poor prognosis of HNSCC [50, 51], 
warranting further investigation. In summary, we have 
reported significantly elevated expression levels of CK 
8 and 18 in saliva collected from HPV-negative patients, 
with simultaneously elevated expression levels of CK 17, 
18 and 19 in saliva collected from HPV-positive HNSCC 
patients. A future longitudinal study is warranted to 
investigate the diagnostic and prognostic values of these 
markers.
MATERIALS AND METHODS
Study design
This study was approved by the University 
of Queensland Medical Ethical Institutional Board 
[HREC No: 2014000679 and 2014000862]; Queensland 
University of Technology [HREC No: 1400000617 and 
1400000641] and by the Princess Alexandra Hospital 
Ethics Review Board [HREC Number: HREC/12/
QPAH/381]. We have recruited (n=68) patients who 
have been diagnosed with HPV-negative and -positive 
HNSCC from the Princess Alexandra Hospital, 
Woolloongabba, Queensland, Australia. In addition, 42 
cancer-free healthy controls (age-matched) were also 
recruited. Participants’ gave written informed consent, 
prior to obtaining samples. Clinical stages of HNSCC 
patients were classified according to the Tumour-Nodal-
Metastasis (TNM) classification of malignant tumours 
of the American Joint Committee on Cancer (AJCC) 
and the HPV status was evaluated by a pathologist 
using standard routine diagnostic testing of p16INK4a 
immunohistochemistry (IHC) as described in our 
previous studies [33].
Oral rinse samples collection and processing
Oral rinse samples were collected from participants 
as described previously [52]. Briefly, participants were 
asked to swish and gargle for 1-2 minutes with 10 ml 0.9% 
saline and subsequently expectorate into a 50 mL falcon 
tube. Samples were immediately kept on dry ice and 
transported back to the laboratory for processing. Samples 
were thawed and centrifuged at 1000 × g for 15 mins at 
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4 °C. Cell pellets were resuspended in 800 μL of Qiazol 
(Qiagen, Germantown, MD, USA) for RNA isolation and 
stored at -80 °C until further analysis.
RNA isolation
Total RNA was isolated from oral exfoliated cell 
pellets using combined method of Qiazol-Chloroform 
(Qiagen) and RNeasy Mini Kit (Qiagen) as per 
manufacturer protocol. Briefly, 130 μL of chloroform 
was added to Qiazol containing oral exfoliated cells 
and centrifuged at maximum speed for 15 mins at 4 °C. 
The resulting aqueous phase was transferred to a clean 
eppendorf tube with an equal volume of 70% ethanol. 
Then, transferred to RNeasy Mini spin columns and 
following the manufacturer’s instructions.
RT-qPCR analysis
RNA (200 ng) was used to synthesize cDNA using 
the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA, 
USA) following the manufacturer’s instructions. qRT-
PCR was carried out with the QuantStudio™ 7 Flex Real-
Time PCR System (Applied Biosystems, Foster City, CA, 
USA). Sense and anti-sense primers targeted against the 
genes of interest are listed in Supplementary Table 1. The 
mRNA transcript level of human beta-actin was used as a 
normalizer.
Statistical analysis
The mRNA expression levels of individual CKs in 
saliva between two cohorts (healthy controls and HNSCC 
patients) were compared using non-parametric analysis 
using Mann-Whitney U-test; while among the three 
cohorts (healthy controls, HPV-negative and -positive 
HNSCC patients) were compared using the ordinary one 
way ANOVA. P-values less than 0.05 were considered 
significant. A receiver operating characteristic (ROC) 
curve was used to discriminate healthy controls from 
HPV-negative HNSCC patients as well as between HPV-
negative and -positive HNSCC patients using the salivary 
CKs mRNA expression levels. All the statistical analysis 
was performed using GraphPad Prism 7 software version 
7 (GraphPad Software Inc., USA) and R Programming.
The hierarchical clustering analysis was determined 
using Morpheus (https://software.broadinstitute.org/
morpheus).
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